Tags

Type your tag names separated by a space and hit enter

Infliximab and Intravenous Gammaglobulin in Hospitalized Severe COVID-19 Patients in Intensive Care Unit.
Arch Iran Med. 2021 Feb 01; 24(2):139-143.AI

Abstract

BACKGROUND

Severe coronavirus disease 2019 (COVID-19) may lead to the cytokine storm syndrome which may cause acute respiratory failure syndrome and death. Our aim was to investigate the therapeutic effects of infliximab, intravenous gammaglobulin (IVIg) or combination therapy in patients with severe COVID-19 disease admitted to the intensive care unit (ICU).

METHODS

In this observational research, we studied 104 intubated adult patients with severe COVID-19 infection (based on clinical symptoms, and radiographic or CT scan parameters) who were admitted to the ICU of a multispecialty hospital during March 2020 in Tehran, Iran. All cases received standard treatment regimens as local protocol (Oseltamivir + hydroxychloroquine + lopinavir/ritonavir or sofosbuvir or atazanavir ± ribavirin). The cases were grouped as controls (n = 43), infliximab (n = 27), IVIg (n = 23) and combination (n = 11).

RESULTS

There was no significant difference between controls and treatment groups in terms of underlying diseases or the number of underlying diseases. The mean age (SD) of cases was 72.42 (16.06) in the control group, 64.52 (12.965) in IVIg, 63.40 (17.57) in infliximab and 64.00 (11.679) in combination therapy; (P = 0.047, 0.031 and 0.11, respectively). Also, 37% in the infliximab group, 26.1% in IVIg, 45.5% in combination therapy, and 62.8% in the control group expired (all P < 0.05). Hazard ratios were 0.31 in IVIg (95% CI: 0.12-0.76, P = 0.01), 0.30 in infliximab (95% CI: 0.13-0.67, P = 0.004), 0.39 in combination therapy (95% CI: 0.12-1.09, P = 0.071).

CONCLUSION

According to the findings of this study, it seems that infliximab and IVIg, alone or together, in patients with severe COVID-19 disease can be considered an effective treatment.

Authors+Show Affiliations

Department of Internal Medicine, Firoozgar Medical and Educational Hospital, Iran University of Medical Sciences, Tehran, Iran.Department of Internal Medicine, Firoozgar Medical and Educational Hospital, Iran University of Medical Sciences, Tehran, Iran.Department of Internal Medicine, Firoozgar Medical and Educational Hospital, Iran University of Medical Sciences, Tehran, Iran.Department of Internal Medicine, Firoozgar Medical and Educational Hospital, Iran University of Medical Sciences, Tehran, Iran.Department of Internal Medicine, Firoozgar Medical and Educational Hospital, Iran University of Medical Sciences, Tehran, Iran.Department of Internal Medicine, Firoozgar Medical and Educational Hospital, Iran University of Medical Sciences, Tehran, Iran.Gastrointestinal and liver Diseases Research Center, Iran University of Medical Sciences, Tehran, Iran.School of Public Health, Isfahan University of Medical Sciences, Isfahan, Iran.Antimicrobial Resistance Research Center, Iran University of Medical Sciences, Tehran, Iran.Antimicrobial Resistance Research Center, Iran University of Medical Sciences, Tehran, Iran.Department of Infectious Diseases, Firoozgar Medical and Educational Hospital, Iran University of Medical Sciences, Tehran, Iran.Antimicrobial Resistance Research Center, Iran University of Medical Sciences, Tehran, Iran.Department of Internal Medicine, Firoozgar Medical and Educational Hospital, Iran University of Medical Sciences, Tehran, Iran.

Pub Type(s)

Journal Article
Observational Study

Language

eng

PubMed ID

33636983

Citation

Farrokhpour, Mohsen, et al. "Infliximab and Intravenous Gammaglobulin in Hospitalized Severe COVID-19 Patients in Intensive Care Unit." Archives of Iranian Medicine, vol. 24, no. 2, 2021, pp. 139-143.
Farrokhpour M, Rezaie N, Moradi N, et al. Infliximab and Intravenous Gammaglobulin in Hospitalized Severe COVID-19 Patients in Intensive Care Unit. Arch Iran Med. 2021;24(2):139-143.
Farrokhpour, M., Rezaie, N., Moradi, N., Ghaffari Rad, F., Izadi, S., Azimi, M., Zamani, F., Izadi, S., Ranjbar, M., Jamshidi Makiani, M., Laali, A., Roham, M., & Yadollahzadeh, M. (2021). Infliximab and Intravenous Gammaglobulin in Hospitalized Severe COVID-19 Patients in Intensive Care Unit. Archives of Iranian Medicine, 24(2), 139-143. https://doi.org/10.34172/aim.2021.22
Farrokhpour M, et al. Infliximab and Intravenous Gammaglobulin in Hospitalized Severe COVID-19 Patients in Intensive Care Unit. Arch Iran Med. 2021 Feb 1;24(2):139-143. PubMed PMID: 33636983.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Infliximab and Intravenous Gammaglobulin in Hospitalized Severe COVID-19 Patients in Intensive Care Unit. AU - Farrokhpour,Mohsen, AU - Rezaie,Nader, AU - Moradi,Najmeh, AU - Ghaffari Rad,Fatemeh, AU - Izadi,Shirin, AU - Azimi,Mehdi, AU - Zamani,Farhad, AU - Izadi,Shahrokh, AU - Ranjbar,Mitra, AU - Jamshidi Makiani,Mahin, AU - Laali,Azadeh, AU - Roham,Maryam, AU - Yadollahzadeh,Mahdi, Y1 - 2021/02/01/ PY - 2020/07/19/received PY - 2020/10/28/accepted PY - 2021/2/27/entrez PY - 2021/2/28/pubmed PY - 2021/3/11/medline KW - COVID-19 KW - Infliximab KW - Intensive care units KW - Intravenous gammaglobulin SP - 139 EP - 143 JF - Archives of Iranian medicine JO - Arch Iran Med VL - 24 IS - 2 N2 - BACKGROUND: Severe coronavirus disease 2019 (COVID-19) may lead to the cytokine storm syndrome which may cause acute respiratory failure syndrome and death. Our aim was to investigate the therapeutic effects of infliximab, intravenous gammaglobulin (IVIg) or combination therapy in patients with severe COVID-19 disease admitted to the intensive care unit (ICU). METHODS: In this observational research, we studied 104 intubated adult patients with severe COVID-19 infection (based on clinical symptoms, and radiographic or CT scan parameters) who were admitted to the ICU of a multispecialty hospital during March 2020 in Tehran, Iran. All cases received standard treatment regimens as local protocol (Oseltamivir + hydroxychloroquine + lopinavir/ritonavir or sofosbuvir or atazanavir ± ribavirin). The cases were grouped as controls (n = 43), infliximab (n = 27), IVIg (n = 23) and combination (n = 11). RESULTS: There was no significant difference between controls and treatment groups in terms of underlying diseases or the number of underlying diseases. The mean age (SD) of cases was 72.42 (16.06) in the control group, 64.52 (12.965) in IVIg, 63.40 (17.57) in infliximab and 64.00 (11.679) in combination therapy; (P = 0.047, 0.031 and 0.11, respectively). Also, 37% in the infliximab group, 26.1% in IVIg, 45.5% in combination therapy, and 62.8% in the control group expired (all P < 0.05). Hazard ratios were 0.31 in IVIg (95% CI: 0.12-0.76, P = 0.01), 0.30 in infliximab (95% CI: 0.13-0.67, P = 0.004), 0.39 in combination therapy (95% CI: 0.12-1.09, P = 0.071). CONCLUSION: According to the findings of this study, it seems that infliximab and IVIg, alone or together, in patients with severe COVID-19 disease can be considered an effective treatment. SN - 1735-3947 UR - https://www.unboundmedicine.com/medline/citation/33636983/Infliximab_and_Intravenous_Gammaglobulin_in_Hospitalized_Severe_COVID-19_Patients_in_Intensive_Care_Unit. L2 - https://medlineplus.gov/covid19coronavirusdisease2019.html DB - PRIME DP - Unbound Medicine ER -